Amicus Therap Us Patent-Cliff Exposure & CMS Drug Spending Portfolio

Amicus Therap Us (US): 1 reconciled FDA prescription therapies, $8.2M 2024 CMS Part D & Medicaid spend, and $1,785 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$8.2M
2024 Medicare Part D Spend$5.8M
2024 Medicaid Spend$2.4M
California HCAI SB 17 FilingsSpecialty launch notice ($1,785 intro WAC)